Seoul National University · Medicine
Professor Jong Woo Hahn's research lab focuses on metabolic and liver diseases, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), with an emphasis on lifestyle interventions, hepatic steatosis, and gut microbiota modulation in pediatric populations. The lab investigates global trends in liver disease-related mortality, especially in under-researched regions like Africa, and explores the impact of environmental and behavioral factors on liver health. Additionally, the lab contributes to public health policy through evidence-based research on tobacco product additives and their health implications.
Figures are computed from collected data and may differ slightly.
National Research Foundation of Korea.
PROSPERO (registration no. CRD42024527805).
Global age-standardized liver disease-related mortality has increased significantly and continues to emerge as a crucial global public health issue. Further investigation into liver disease-related mortality rates in Africa is needed, and updating policies is necessary to effectively manage the global burden of liver disease.
Abstract Additives used in tobacco product manufacturing are currently in the focus of public discussions with regard to potentially increased consumer health risks on account of certain additives. In addition, a few additives are suspected to enhance the addictiveness of tobacco products. In 2006, the German Federal Ministry for Food, Agriculture and Consumer Protection (BundesministeriumfuerErnaehrung, Landwirtschaft und Verbraucherschutz, BMELV) commissioned a research project intended to pro
Lifestyle modifications are fundamental in managing metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to evaluate the effects of a 12-week lifestyle intervention on hepatic steatosis, liver function, and gut microbiota composition in pediatric MASLD patients, and to explore clinical and baseline microbial features associated with treatment response. A total of 40 patients were recruited, and 31 were included after applying exclusion criteria. After 12 weeks, sign
Supplementary Material 1.
Introduction: The incidence and severity of Clostridioides difficile infection (CDI) have been increasing over the past decades. It particularly contributes to acute exacerbations and worsen the severity of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is one of standard treatments for recurrent CDI. The aim of this study was to evaluate the clinical outcome of FMT for recurrent CDI in pediatric patients with refractory IBD. Methods: From May 2013 through April 2023, w
Supplementary Material 1.
Supplementary Material 2.
Supplementary Material 2.
Open papers in the app to read, cite, and organize with AI.
